AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 23 min read$OKLO

DeWitte Jacob sold $4.1M of OKLO

DeWitte Jacob (Co-Founder, CEO) sold 60,000 shares of Oklo Inc. (OKLO) at $68.29 ($4.10M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · DeWitte Jacob
Published Jun 2, 2026, 9:10 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 2, 2026, 9:13 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$OKLO
Neutral
medium confidence
Mentioned
$OKLO
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OKLONeutralLow
01

Why it matters

The disclosure can affect short-term sentiment, but 10b5-1 reduces the likelihood of it being a new, information-driven signal.

02

Market read

A $4.1M insider sale was disclosed; traders may monitor for follow-on selling or changes in insider/holder behavior.

03

What to watch

The filing does not reveal motivations or whether other insiders/large holders changed positions; also, share price reaction may depend on whether the market was already expecting insider selling.

Relevance 6/10Novelty 7/10Timing: Filed after-hours/late day (2026-06-02 17:10 ET) disclosing a 2026-06-01 sale

Background

SEC Form 4 reports insider transactions for Oklo; the sale was executed under a Rule 10b5-1 plan.

Company-level read

Ticker impact

$OKLONeutralMedium confidence
Context

Oklo co-founder/CEO DeWitte Jacob sold 60,000 shares in an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited near-term price impact; could add mild overhang if market interprets as reduced conviction.

Evidence & confidence

The filing is a routine insider sale with 10b5-1 pre-arrangement, providing less surprise than unscheduled selling; however, size/value ($4.1M) can still influence sentiment.

Market effects

Sector

Minimal; this is company-specific insider liquidity/positioning rather than sector-wide catalyst.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale was executed under a pre-arranged 10b5-1 plan, it may reflect scheduled diversification/liquidity needs rather than negative outlook.

Key entities

  • issuer
    Oklo Inc.

    Subject of the Form 4 insider sale by its co-founder/CEO.

  • insider
    DeWitte Jacob

    Co-founder, CEO, officer/director/10% owner who sold shares.

Read at source← All news

Related articles

AUG 9
$OKLOMed

Oklo’s Groves Research Reactor Achieves First Criticality

Oklo (NYSE: OKLO) said its Groves Isotope Test Reactor reached first criticality on private land, supported by DOE Reactor Pilot Program authorization. Los Alamos’ ZiaCore microreactor also achieved zero-power criticality. ARC Clean Technology (ARC) outlined plans for ARC-100 at INL and a term sheet for Turkey. Holtec, Entergy and Hyundai will evaluate SMR-300 projects in Gulf states.

neutronbytes.com6 min
AUG 7
$OKLOMed

Oklo Inc. Q2 2026 Earnings Call Summary

Oklo Inc. reported progress from its Q2 2026 earnings call, including first criticality at the Groves isotope facility and plans for Aurora deployments at INL and an Ohio clean energy campus. The company targeted 2028 commercial startup, expected first isotope revenue in early 2027, and raised 2026 operating cash use guidance to $120M-$150M and PP&E spend to $400M-$500M.

yahoo.com10 min
AUG 7
$OKLOMed

Oklo Stock Attempts a Turnaround, but Technical Barriers Remain as It Releases Q2 2026 Financial Results

Oklo reported Q2 2026 revenue of $1.2 million, above analysts’ ~$83,800 estimate, but posted a $0.28 per-share loss versus a ~$0.16 consensus. Net loss widened to $48.5 million from $24.7 million a year earlier. The company ended the quarter with about $3 billion in cash and marketable securities and said its Groves Isotope Test Reactor achieved first criticality.

fxleaders.com6 min
AUG 7
$OKLOMedAI 8/10

Oklo reports $1.21M Q2 revenue, $1.6B cash as Aurora milestones advance

Oklo Inc. (NYSE: OKLO) reported Q2 2026 revenue of $1.21M versus a $126,250 analyst estimate and an EPS loss of $(0.28) versus an estimated $(0.16). The company said it ended the quarter with $1.6B cash and expects 2026 operating cash flow of $120M to $150M and capex of $400M to $500M. It also advanced Aurora regulatory steps and said its Groves reactor reached first criticality.

scanx.trade7 min